Oxford Nanopore Technologies plc

London Calling Technology Update

Annual customer conference highlights how Oxford Nanopore's unique molecular sensing platform empowers real-time insights, consistent results, and multiomic discovery

22 May 2025

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Company"), the company delivering a new generation of nanopore-based molecular sensing technology, presented technology and platform updates at the Company's flagship annual London Calling customer conference. During the sold-out event, with more than 4,500 registered online and in-person participants from more than 120 countries, the Company also provided updates to its long-term innovation pipeline.

Technology and pipeline updates included: 

·      Continued enhancement to product performance, reliability and competitiveness: The presentation highlighted the development of high throughput workflows, flow cell improvements and new kit chemistries to drive higher output on the PromethION Flow Cell.

·      Improved analytics and insights for broad applications: Continued development of EPI2ME, the Company's informatics platform which provides analysis tools for a growing menu of end-to-end workflows. Updates included (i) a new high-performance variant caller to increase consistency and accelerate workflows, especially in production environments where speed and reproducibility are key drivers and (ii) continued development of base modification calling, with more than ten modifications now supported. This enables improved accuracy of methylation detection, without the need for complex processes required with legacy sequencing technologies.

·      Improving direct RNA sequencing, to accelerate biopharma workflows with a single streamlined platform: Recent updates to the cDNA kit and direct RNA workflows enable longer reads and higher output, delivering industry-leading performance supporting biopharma applications beyond mRNA Vaccine Quality Control, including drug discovery, sterility testing, and exploring tissue-specific RNA modifications.

·      Near term focus on regulated product pipeline to driving adoption in applied markets: The GridION Q device is expected to complete CE-IVD submission in the EU for regulated clinical markets by the end of 2025. The device will be available for specified partners only. The Q-Line product range is expanding to include PromethION Q, now expected to launch in 2026, to broaden the opportunity for human sequencing applications.

·      Ambitious and targeted long-term innovation pipeline: including the ongoing development of a new voltage-controlled ASIC for high throughput customers.

·      A roadmap to proteomics: Oxford Nanopore is now making advancements into providing solutions for protein analysis, a key area for scientific research and discovery in health and substantial potential for applied uses in clinical and industrial applications. The Company is currently developing two complementary approaches: one focused on identifying native proteins in clinical samples, and another designed for scalable protein barcoding. Both workflows are in development, with future potential to enable the direct detection and characterisation of full-length proteins.

A detailed written summary and a video replay of the technology talk can be accessed on the Oxford Nanopore website here.

-ENDS-

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:      ir@nanoporetech.com

Media:           media@nanoporetech.com

Teneo (communications adviser to the Company)

Tom Murray, Jo Blackshaw and Lisa Jarrett-Kerr

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit: www.nanoporetech.com

Forward-looking statements

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, delays or challenges in manufacturing or delivering of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance or applied uses of our products. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.